News
Public · Published
Truist Securities maintains Madrigal Pharmaceuticals at Buy, raises price target to $743 from $709
Truist Securities kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $743 from $709, a 4.8% increase. The new target implies 87.5% upside from the November 3 closing price of $396.32.
Published:
Updated:
What happened
Truist Securities kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $743 from $709, a 4.8% increase. The new target implies 87.5% upside from the November 3 closing price of $396.32.
Confirmed
Global impact / market context
The higher target signals that Truist sees more potential share-price appreciation while keeping its positive rating. If investors respond by buying shares, Madrigal’s stock could gain support; however, an analyst target is an estimate, not a guaranteed outcome or a company forecast.
Analyst inference
The update changes Truist’s valuation view, not the company’s reported business results. The implied 87.5% upside compares its target with the November 3 close, so it reflects that reference price and does not establish how the shares have traded since then.
Analyst inference
What to watch
- Watch for Madrigal’s future company updates, which could provide evidence that supports or challenges the expectations behind Truist’s higher target. Analyst inference
- Check whether other analysts change their ratings or targets; the article reports only Truist’s decision and provides no broader analyst consensus. Analyst inference
- Compare the share price with the $743 target over time, remembering that the target is an analyst estimate rather than a promised return. Analyst inference
Evidence
- Original source link unavailable